ProCE Banner Activity

Evaluation of the Prognostic and Predictive Value of PAM50 Intrinsic Subtypes and ROR Scores in Premenopausal Women With HR+/HER2- Early Breast Cancer Enrolled in the SOFT Trial

Conference Coverage

In this secondary analysis of the cohort of premenopausal patients with HR+/HER2- breast cancer in the SOFT trial, the PAM50 ROR scores had prognostic value but were not predictive of OFS benefit.

Released: June 06, 2023


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Gilead and Merck Sharp & Dohme Corp.


Daiichi Sankyo


Merck Sharp & Dohme Corp.